Bone marrow cell-mediated cardiovascular repair: potential of combined therapies

Claudio Napoli, Ciro Maione, Concetta Schiano, Carmela Fiorito, Louis J. Ignarro

Research output: Contribution to journalArticlepeer-review


Recent evidence indicates that bone-marrow cells (BMCs) can contribute to the healing process of the injured cardiovascular system via the chemokine receptor CXCR4/SDF-1, thymosin β 4 and integrin α 4β 1 molecular pathways. During tissue ischemia overwhelming numbers of detrimental oxygen radicals are generated, and therefore treatment with antioxidants and L-arginine, the precursor of nitric oxide (NO), could induce beneficial effects beyond those achieved by BMC transplantation alone. Recent studies have reported that BMCs have enhanced neovascularization capacity in cotreatment with α-tocopherol (vitamin E), ascorbic acid (vitamin C) and L-arginine. Moreover, BMC therapy can be combined with gene therapy. Clinical trials employing BMCs in the treatment of cardiovascular diseases have been completed with mixed or positive results, and several trials are ongoing. Here, we discuss the clinical potential of BMC transplantation alone and in combined therapy that aims to restore organ vascularization and function. We also consider the mechanisms of mobilization, differentiation and incorporation of BMCs.

Original languageEnglish
Pages (from-to)278-286
Number of pages9
JournalTrends in Molecular Medicine
Issue number7
Publication statusPublished - Jul 2007

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Bone marrow cell-mediated cardiovascular repair: potential of combined therapies'. Together they form a unique fingerprint.

Cite this